Abstract library

876 results for "clinical practice".
#641 Metastatic Gastroenteropancreatic Neuroendocrine Tumors (GEP NETs) Management in a Spanish University Hospital
Introduction: GEP-NETs are malignant entities poorly understood still, deserving important attention for a better management of the disease.
Conference: 10th Annual ENETS Conference (2013)
Category: Medical treatment – Chemotherapy, medical treatment - others
Presenting Author: Msc MD María Del Pilar Solis-Hernandez
Authors:
#2034 International Survey of Clinical Practice Exploring Use of Platinum-Etoposide Chemotherapy for Extra-Pulmonary High Grade Neuroendocrine Carcinoma (EP-G3-NEC)
Introduction: Platinum-etoposide (PE) chemotherapy (CH) is a globally established combination for EP-G3-NEC; the optimal schedule has not been established.
Conference: 15th Annual ENETS conference (2018)
Category: Medical treatment - Chemotherapy Somatostatin analogues, Interferon
Presenting Author: Dr Angela Lamarca
Authors:
#1696 On-going Evaluation of The Clinical Utility of the Health-Related Quality-Of-Life (HRQoL) QLQ-GINET21 Questionnaire (QNR) in the Treatment of Patients (pts) with Gastrointestinal (GI) Neuroendocrine Tumours (NETs). QUALINETS Study
Introduction: Outcome measures reported by pts help to weigh benefit/effect of a therapy on quality of life (QoL), provided that their utility in clinical practice is proved. There are few QoL QNRs for pts with NETs, like QLQ-GINET21, with 21 items assessing muscle/bone pain, body image, information, sexual function, symptoms, social function and disease-related concerns.
Conference: 14th Annual ENETS conference (2017)
Category: ...none of the above
Presenting Author: Dr. Javier Gallego
Authors:
#1184 A National Pathology Registration Analysis of Applied Terminology in Pulmonary Neuroendocrine Tumors/Carcinomas: Is the WHO 2004 Classification in Line with Clinical Practice?
Introduction: Nomenclature of the WHO 2004 should be used for pulmonary neuro-endocrine tumors (NET) and carcinomas (NEC) classification.
Conference: 12th Annual ENETS Conference (2015)
Category: Non digestive NETs (bronchial, MTC, pheochromocytoma)
Presenting Author: MD Jules Derks
Authors:
Keywords: NET, Diagnosis
#1417 Everolimus (EVE) Safety Profile in Patients (pts) with Advanced G1-G2 Neuroendocrine Tumours (NETs) from Daily Clinical Practice
Introduction: EVE has shown an overall favourable and well-characterized safety profile in randomized studies including advanced G1-G2 NETs. However, few data outside regulatory trials are available.
Conference: 13th Annual ENETS conference (2016)
Category: Medical treatment - Targeted therapies
Presenting Author: MD PhD Ana Custodio
Authors:
#1270 Clinicopathological Features and Prognostic Factors of Colorectal Neuroendocrine Neoplasms in China
Introduction: Limited research is available regarding colorectal neuroendocrine neoplasms (NENs), especially in China.
Conference: 13th Annual ENETS conference (2016)
Category: Epidemiology/Natural history/Prognosis - Prognosis
Presenting Author: M.D. Mengjie Jiang
Authors:
#1541 Comparing Real-life Practice to Established Guidelines in the Management of Gasteroenteropancreatic Neuroendocrine Cancer Patients: A Tertiary Cancer Center Experience
Introduction: Guidelines by ENETS in the management of Gastroenteropancreatic Neuroendocrine Tumors (GP-NETS) are intended as a clinical tool to practice evidence-based medicine. Its adaptability and translation in real-life setting has yet to be examined.
Conference: 13th Annual ENETS conference (2016)
Category: ...none of the above
Presenting Author: MD.Ph.D Petr Kavan
Authors:
#498 Limitations of Chromogranin A in Clinical Practice
Introduction: Chromogranin-A (CgA) is the most accurate marker for the histological diagnosis of neuroendocrine tumors (NETs). However diagnostic usefulness of circulating CgA is controversial as several conditions, both neoplastic and non-neoplastic, may induce false positive increases of this marker.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Dr Vincenzo Marotta
Authors:
#868 Role of 68Ga-DOTATATE PET/TC (68Ga-PET-CT) for the Management of Patients with Neuroendrocrine Tumors (NETs): Impact in Therapeutic Decisions of our Clinical Practice
Introduction: 68Ga-PET-CT has demonstrated a higher diagnostic accuracy than any other imaging procedures (CT/MRI/SRS). ARGENTUM group described their experience with 68Ga-PET-CT in eight patients with advanced Gastroenteropancreatic Neuroendocrine Tumors (ENETS 2011). Conclusion was that 68Ga-PET-CT enabled changes in the strategy of treatment in all cases. The impact of 68Ga-PET-CT on the therapeutic management in NETs is constantly under evaluation.
Conference: 11th Annual ENETS Conference (2014)
Category: Clinical cases/reports
Presenting Author: MD Claudia Bestani
Authors:
#1175 Population Pharmacokinetic (PK) Analysis of Lanreotide Autogel (LAN) in the Treatment of Patients (pts) with NETs: Pooled Analysis of Four Clinical Trials
Introduction: LAN provide antitumor effects and symptom control in NET pts.
Conference: 12th Annual ENETS Conference (2015)
Category: Medical treatment - SMS analogues, interferon
Presenting Author: Nuria Buil-Bruna
Authors:
Keywords: PK, dosing